AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31996311 — intervention group
Group type: EXPERIMENTAL
Intervention: Resveratrol (150 mg/day)
Number of subjects: 21
Study 31996311 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 28898473 — intervention group
Group type: EXPERIMENTAL
Intervention: Prucalopride (4 mg oral)
Number of subjects: 15
Study 28898473 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 26990378 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin degludec (IDeg) add-on to liraglutide
Number of subjects: 346
Study 26990378 — intervention group
Group type: COMPARATOR
Intervention: Placebo add-on to liraglutide
Number of subjects: 346
Study 26585622 — intervention group
Group type: EXPERIMENTAL
Intervention: Scaffold oversize group (Dmax smaller than nominal size)
Number of subjects: 1248
Study 26585622 — intervention group
Group type: COMPARATOR
Intervention: Scaffold nonoversize group (Dmax larger than nominal size)
Number of subjects: 1248
Study 26585622 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 1248
Study 26585622 — intervention group
Group type: EXPERIMENTAL
Intervention: Scaffold oversize group
Number of subjects: 1248
Study 26585622 — intervention group
Group type: EXPERIMENTAL
Intervention: Overlapping scaffolds
Number of subjects: 1248
Study 23992602 — intervention group
Group type: EXPERIMENTAL
Intervention: Alogliptin
Number of subjects: 5380
Study 23992602 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5380
Study 20877931 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfeeding promotion program
Number of subjects: 200
Study 20877931 — intervention group
Group type: EXPERIMENTAL
Intervention: Mothers unable to nurse during work shift
Number of subjects: 200
Study 19093000 — intervention group
Group type: EXPERIMENTAL
Intervention: Acromegaly (AM) group
Number of subjects: 7
Study 19093000 — intervention group
Group type: COMPARATOR
Intervention: Healthy control (CON) group
Number of subjects: 7
Study 16626797 — intervention group
Group type: EXPERIMENTAL
Intervention: Proactive telephone-based peer counseling intervention with up to 6 counseling calls and nicotine replacement therapy (NRT) patches if prepared to quit smoking
Number of subjects: 398
Study 16626797 — intervention group
Group type: EXPERIMENTAL
Intervention: NRT
Number of subjects: 398
Study 16626797 — intervention group
Group type: EXPERIMENTAL
Intervention: Demographic variables (females, White), higher daily smoking rate, poorer perceived health and moderate perceived risk of smoking
Number of subjects: 398
Study 12792581 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil (0.1 microg/kg/min)
Number of subjects: 60
Study 12792581 — intervention group
Group type: COMPARATOR
Intervention: Alfentanil (0.75 microg/kg/min)
Number of subjects: 60
Study 12792581 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil and alfentanil in association with propofol
Number of subjects: 60
Study 10367557 — intervention group
Group type: EXPERIMENTAL
Intervention: d-amphetamine (20 mg)
Number of subjects: 36
Study 10367557 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 8669996 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 minutes of static stretching exercises interspersed with relaxing (10 subjects)
Number of subjects: 16
Study 8669996 — intervention group
Group type: COMPARATOR
Intervention: Control group (6 subjects, untreated)
Number of subjects: 16
Study 1716810 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmonella typhi Ty21a/V. cholerae Inaba (EX210) vaccine
Number of subjects: 0
Study 1716810 — intervention group
Group type: EXPERIMENTAL
Intervention: Galactose concentration in media
Number of subjects: 0
Study 1716810 — intervention group
Group type: EXPERIMENTAL
Intervention: S. typhi Ty21a O antigen
Number of subjects: 0
Study 6412494 — intervention group
Group type: EXPERIMENTAL
Intervention: Total parenteral nutrition (TPN)
Number of subjects: 0
Study 29898692 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-weekly sessions of protocolized interpersonal psychotherapy (IPT)
Number of subjects: 15
Study 29898692 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-weekly sessions of cognitive behavioral therapy (CBT)
Number of subjects: 15
Study 29898692 — intervention group
Group type: COMPARATOR
Intervention: Once-weekly sessions of protocolized IPT and CBT
Number of subjects: 15
Study 26435055 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant therapy (10-day regimen)
Number of subjects: 364
Study 26435055 — intervention group
Group type: COMPARATOR
Intervention: Sequential therapy (10-day regimen)
Number of subjects: 364
Study 24845177 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower heart rate variability (HRV)
Number of subjects: 84
Study 24845177 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart rate variability (HRV)
Number of subjects: 84
Study 24845177 — intervention group
Group type: EXPERIMENTAL
Intervention: Inflammation (IL-6 and CRP)
Number of subjects: 84
Study 22672993 — intervention group
Group type: EXPERIMENTAL
Intervention: Assisted hatching (AH)
Number of subjects: 60
Study 22672993 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study 20536957 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-monitoring of blood glucose (SMBG) using premixed insulin lispro mixtures
Number of subjects: 623
Study 20536957 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-monitoring of blood glucose (SMBG) using basal insulin glargine
Number of subjects: 623
Study 20536957 — intervention group
Group type: EXPERIMENTAL
Intervention: Means of two or more plasma equivalent glucose (PGe) measures
Number of subjects: 623
Study 20536957 — intervention group
Group type: EXPERIMENTAL
Intervention: Receiver-operating characteristic (ROC) curves for PGe to estimate HbA(1c) (< or > 7.0%)
Number of subjects: 623
Study 20536957 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall HbA(1c) measurement
Number of subjects: 623
Study 18728175 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle modification
Number of subjects: 79
Study 18728175 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral contraceptives (OCs)
Number of subjects: 79
Study 18728175 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle modification + OCs + Metformin
Number of subjects: 79
Study 18728175 — intervention group
Group type: COMPARATOR
Intervention: Combined treatment and placebo
Number of subjects: 79
Study 15717881 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention (L)
Number of subjects: 38
Study 15717881 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention + insulin treatment (L+I)
Number of subjects: 38
Study 15717881 — intervention group
Group type: COMPARATOR
Intervention: Insulin treatment alone (I)
Number of subjects: 38
Study 12187204 — intervention group
Group type: EXPERIMENTAL
Intervention: Transurethral resection plus 100 mg epirubicin
Number of subjects: 200
Study 12187204 — intervention group
Group type: EXPERIMENTAL
Intervention: Transurethral resection plus 50 milliunits interferon-alpha2b
Number of subjects: 200
Study 12187204 — intervention group
Group type: COMPARATOR
Intervention: Transurethral resection alone
Number of subjects: 200
Study 10458419 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopy and open surgery (group 2)
Number of subjects: 61
Study 10458419 — intervention group
Group type: COMPARATOR
Intervention: Open surgery only (group 1)
Number of subjects: 61
Study 7869850 — intervention group
Group type: EXPERIMENTAL
Intervention: New generation combined oral contraceptives (OC)
Number of subjects: 0
Study 7869850 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral protein load in OC users
Number of subjects: 0
Study 7869850 — intervention group
Group type: COMPARATOR
Intervention: Control group (comparable controls)
Number of subjects: 0
Study 2782342 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic transcervical amnioinfusion
Number of subjects: 0
Study 787014 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoprofen calcium (200, 400, or 600 mg)
Number of subjects: 30
Study 787014 — intervention group
Group type: EXPERIMENTAL
Intervention: Propoxyphene napsylate (50, 100, or 150 mg)
Number of subjects: 30
Study 787014 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoprofen calcium
Number of subjects: 30
Study 787014 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoprofen calcium and Propoxyphene napsylate (combined)
Number of subjects: 30
Study 787014 — intervention group
Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 30
Study 31495887 — intervention group
Group type: EXPERIMENTAL
Intervention: β-blocker use
Number of subjects: 5862
Study 31495887 — intervention group
Group type: EXPERIMENTAL
Intervention: β-blocker use (eGFR >60)
Number of subjects: 5862
Study 31495887 — intervention group
Group type: EXPERIMENTAL
Intervention: β-blocker use (eGFR 30-60)
Number of subjects: 5862
Study 31495887 — intervention group
Group type: EXPERIMENTAL
Intervention: β-blocker use (eGFR <30)
Number of subjects: 5862
Study 30634618 — intervention group
Group type: EXPERIMENTAL
Intervention: E-cigarette ads with 'brain' warning theme
Number of subjects: 876
Study 30634618 — intervention group
Group type: EXPERIMENTAL
Intervention: E-cigarette ads with 'chemicals' warning theme
Number of subjects: 876
Study 30634618 — intervention group
Group type: EXPERIMENTAL
Intervention: E-cigarette ads with 'relative harm warning' statement
Number of subjects: 876
Study 30634618 — intervention group
Group type: COMPARATOR
Intervention: E-cigarette ads with 'standard warning' (absence of RH statement)
Number of subjects: 876
Study 26609668 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral weight loss interventions (PREFER, SELF, SMART)
Number of subjects: 504
Study 25233649 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy of acupuncture at Xiaojie point and tendon regulation manipulation
Number of subjects: 60
Study 25233649 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture at Xiaojie point
Number of subjects: 60
Study 25233649 — intervention group
Group type: COMPARATOR
Intervention: Tendon-regulation manipulation
Number of subjects: 60
Study 22004474 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse specialists as central caregivers
Number of subjects: 0
Study 22004474 — intervention group
Group type: COMPARATOR
Intervention: Usual care (physicians)
Number of subjects: 0
Study 20113920 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV vaccine coadministered with dTpa-IPV
Number of subjects: 751
Study 20113920 — intervention group
Group type: COMPARATOR
Intervention: dTpa-IPV alone
Number of subjects: 751
Study 20113920 — intervention group
Group type: COMPARATOR
Intervention: HPV vaccine alone
Number of subjects: 751
Study 20113920 — intervention group
Group type: EXPERIMENTAL
Intervention: Coadministration of HPV vaccine and dTpa-IPV
Number of subjects: 751
Study 17544329 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (5 mg/kg)
Number of subjects: 30
Study 17544329 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 16161914 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary PTCA
Number of subjects: 40
Study 16161914 — intervention group
Group type: COMPARATOR
Intervention: Thrombolysis
Number of subjects: 40
Study 14512127 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 800 pg/d, reduced to 400 pg/d and then 200 pg/d if asthma control maintained
Number of subjects: 197
Study 14512127 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone 800 pg/d, reduced to 400 pg/d and then 200 pg/d if asthma control maintained
Number of subjects: 197
Study 10944100 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral anticoagulants or aspirin after infrainguinal bypass surgery
Number of subjects: 2650
Study 10944100 — intervention group
Group type: EXPERIMENTAL
Intervention: Femoropopliteal bypasses
Number of subjects: 2650
Study 10944100 — intervention group
Group type: EXPERIMENTAL
Intervention: Femorocrural bypass grafts
Number of subjects: 2650
Study 10944100 — intervention group
Group type: COMPARATOR
Intervention: First model (history and clinical examination)
Number of subjects: 2650
Study 10944100 — intervention group
Group type: EXPERIMENTAL
Intervention: Second model (including radiological and surgical data)
Number of subjects: 2650
Study 2070391 — intervention group
Group type: EXPERIMENTAL
Intervention: Buffered lidocaine
Number of subjects: 20
Study 2070391 — intervention group
Group type: COMPARATOR
Intervention: Standard lidocaine
Number of subjects: 20
Study 6342398 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure patching
Number of subjects: 41
Study 6342398 — intervention group
Group type: COMPARATOR
Intervention: Unpatched group (control)
Number of subjects: 41
Study 6342398 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with bullous keratopathy
Number of subjects: 41
Study 30639342 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone gel
Number of subjects: 93
Study 30639342 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 93
Study 29937195 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalised e‐health‐care programme
Number of subjects: 344
Study 29937195 — intervention group
Group type: COMPARATOR
Intervention: Usual care and access to a placebo website
Number of subjects: 344
Study 26636426 — intervention group
Group type: EXPERIMENTAL
Intervention: Group Cognitive Processing Therapy - Cognitive only version (CPT-C)
Number of subjects: 108
Study 26636426 — intervention group
Group type: COMPARATOR
Intervention: Group Present-Centered Therapy (PCT)
Number of subjects: 108
Study 24998546 — intervention group
Group type: COMPARATOR
Intervention: Comprehensive-SFL state
Number of subjects: 898
Study 24998546 — intervention group
Group type: EXPERIMENTAL
Intervention: SHS exposure in public transport
Number of subjects: 898
Study 22970177 — intervention group
Group type: EXPERIMENTAL
Intervention: Fully integrated services (ANC, PMTCT, and HIV treatment services all delivered in the ANC clinic)
Number of subjects: 1172
Study 22970177 — intervention group
Group type: COMPARATOR
Intervention: Non-integrated services (ANC clinics provided ANC and basic PMTCT services and referred clients to a separate HIV clinic for HIV treatment)
Number of subjects: 1172
Study 20233625 — intervention group
Group type: EXPERIMENTAL
Intervention: High immunohistochemical (IHC) expression of cyclin E
Number of subjects: 0
Study 20233625 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-detectable immunoblot expression of maspin
Number of subjects: 0
Study 20233625 — intervention group
Group type: EXPERIMENTAL
Intervention: High CD105-microvessel density (MVD) in tumor
Number of subjects: 0
Study 20233625 — intervention group
Group type: EXPERIMENTAL
Intervention: Low IHC expression of BRCA1
Number of subjects: 0
Study 20233625 — intervention group
Group type: EXPERIMENTAL
Intervention: CA/AA versus CC genotypes in C8092A in ERCC1
Number of subjects: 0
Study 17341568 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 microg PYY(3‐36) t.i.d.
Number of subjects: 133
Study 17341568 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 microg PYY(3‐36) t.i.d.
Number of subjects: 133
Study 17341568 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 133
Study 15531753 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP200), 200 microg daily for 3 months
Number of subjects: 65
Study 15531753 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study 15531753 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP200)
Number of subjects: 65
Study 11985942 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronutrient-containing beverage (12 oz daily for 6 weeks)
Number of subjects: 31
Study 11985942 — intervention group
Group type: COMPARATOR
Intervention: Placebo (12 oz daily for 6 weeks)
Number of subjects: 31
Study 11985942 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronutrient-containing beverage
Number of subjects: 31
Study 9805319 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehearsal
Number of subjects: 12
Study 9805319 — intervention group
Group type: COMPARATOR
Intervention: Reading control task
Number of subjects: 12
Study 9805319 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehearsal and reading rates
Number of subjects: 12
Study 9805319 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehearsal list length
Number of subjects: 12
Study 7720911 — intervention group
Group type: EXPERIMENTAL
Intervention: Expanded polytetrafluoroethylene (PTFE; Gore‐Tex Surgical Membrane)
Number of subjects: 32
Study 7720911 — intervention group
Group type: COMPARATOR
Intervention: Oxidized regenerated cellulose (Interceed TC7)
Number of subjects: 32
Study 1962277 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 Gy per fraction
Number of subjects: 203
Study 1962277 — intervention group
Group type: EXPERIMENTAL
Intervention: 5.4 Gy per fraction
Number of subjects: 203
Study 1962277 — intervention group
Group type: EXPERIMENTAL
Intervention: Various fractionation regimens (2 Gy, 3 Gy, 4 Gy, 5.4 Gy)
Number of subjects: 203
Study 6786796 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunisolide nasal spray
Number of subjects: 67
Study 6786796 — intervention group
Group type: COMPARATOR
Intervention: Sodium cromoglycate nasal spray
Number of subjects: 67
Study 30978438 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate Dentin Sealing (IDS)
Number of subjects: 60
Study 30978438 — intervention group
Group type: COMPARATOR
Intervention: Delayed Dentin Sealing (DDS)
Number of subjects: 60
Study 28665038 — intervention group
Group type: EXPERIMENTAL
Intervention: M. chamomilla L., M. officinalis L. and tyndallized L. acidophilus (HA122) (Colimil® Plus®)
Number of subjects: 176
Study 28665038 — intervention group
Group type: EXPERIMENTAL
Intervention: L. reuteri DSM 17938
Number of subjects: 176
Study 28665038 — intervention group
Group type: COMPARATOR
Intervention: Simethicone
Number of subjects: 176
Study 28665038 — intervention group
Group type: EXPERIMENTAL
Intervention: M. chamomilla L., M. officinalis L. and tyndallized L. acidophilus (HA122)
Number of subjects: 176
Study 27686173 — intervention group
Group type: EXPERIMENTAL
Intervention: On-site support for laboratory staff
Number of subjects: 128
Study 24812193 — intervention group
Group type: EXPERIMENTAL
Intervention: Mii‐vitaliSe intervention (Nintendo Wii)
Number of subjects: 30
Study 24812193 — intervention group
Group type: COMPARATOR
Intervention: Control group (delayed intervention after 6 months)
Number of subjects: 30
Study 21412266 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan (12 mg per day)
Number of subjects: 0
Study 21412266 — intervention group
Group type: COMPARATOR
Intervention: Candesartan (8 mg per day) plus amlodipine (2.5 mg per day)
Number of subjects: 0
Study 19347682 — intervention group
Group type: EXPERIMENTAL
Intervention: General practitioners' adherence to clinical guidelines for dementia diagnosis and management
Number of subjects: 450
Study 19347682 — intervention group
Group type: EXPERIMENTAL
Intervention: Documentation of the diagnostic process in dementia syndromes
Number of subjects: 450
Study 19347682 — intervention group
Group type: EXPERIMENTAL
Intervention: Management processes for dementia in primary care
Number of subjects: 450
Study 17634896 — intervention group
Group type: EXPERIMENTAL
Intervention: MML group (moxifloxacin 400 mg/d, metronidazole 400 mg twice daily, lansoprazole 30 mg twice daily)
Number of subjects: 277
Study 17634896 — intervention group
Group type: EXPERIMENTAL
Intervention: MAL group (moxifloxacin 400 mg/d, amoxicillin 1 g twice daily, lansoprazole 30 mg twice daily)
Number of subjects: 277
Study 17634896 — intervention group
Group type: COMPARATOR
Intervention: CML group (clarithromycin 500 mg twice daily, metronidazole 400 mg twice daily, lansoprazole 30 mg twice daily)
Number of subjects: 277
Study 17634896 — intervention group
Group type: COMPARATOR
Intervention: CAL group (clarithromycin 500 mg twice daily, amoxicillin 1 g twice daily, lansoprazole 30 mg twice daily)
Number of subjects: 277
Study 15163941 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote echocardiography using a handheld echocardiographic device with satellite transmission
Number of subjects: 12
Study 11722487 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical skin lipid mixture containing ceramide‐3 and patented nanoparticles
Number of subjects: 580
Study 11722487 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical skin lipid mixture in combination with topical corticosteroids
Number of subjects: 580
Study 11722487 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin lipid mixture
Number of subjects: 580
Study 11722487 — intervention group
Group type: COMPARATOR
Intervention: Control (Topical corticosteroids alone)
Number of subjects: 580
Study 9826042 — intervention group
Group type: EXPERIMENTAL
Intervention: Phacoemulsification
Number of subjects: 42
Study 9826042 — intervention group
Group type: COMPARATOR
Intervention: ECCE
Number of subjects: 42
Study 8016425 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiopental 4 mg/kg
Number of subjects: 100
Study 8016425 — intervention group
Group type: COMPARATOR
Intervention: Propofol 2 mg/kg
Number of subjects: 100
Study 2314578 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine
Number of subjects: 15
Study 2314578 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenobarbital
Number of subjects: 15
Study 2314578 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenytoin
Number of subjects: 15
Study 2314578 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 15
Study 372867 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac 25 mg q.i.d.
Number of subjects: 24
Study 372867 — intervention group
Group type: COMPARATOR
Intervention: Aspirin 750 mg q.i.d.
Number of subjects: 24
Study 31989580 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioural change programme plus moisturizing creams
Number of subjects: 2040
Study 31989580 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 2040
Study 31407876 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized multicomponent exercise training programme (performed during 5-7 consecutive days, two sessions/day)
Number of subjects: 370
Study 31407876 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized multicomponent exercise training programme
Number of subjects: 370
Study 31407876 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual care)
Number of subjects: 370
Study 31407876 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (exercise intervention)
Number of subjects: 370
Study 28295451 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK3050002 (0.1-20 mg kg-1)
Number of subjects: 48